This could indicate that (1) increases in CSF YKL-40 and plasma GFAP reflect distinct populations of astrocytes with unique responses to different AD-related pathologies, and (2) plasma GFAP could be a marker of Aβ pathology. Here, GFAP is linked to Alzheimer disease.